Alice Lin PomponioAdvisor at Red Sky Partners; Founder and Managing Director at Accendo
Alice Lin Pomponio optimizes company value proposition and market impact through patient centric strategies that modernize drug development and improve outcomes. She expertly aligns shared mission across entities to enhance patient engagement, operationalize innovative public-private partnerships, improve economic and societal value, and overcome system-level barriers. Recognized for her broad and deep industry knowledge, out-of-the-box thinking, strategic alliance development, novel fundraising, and establishment of governance boundaries, Alice is a trusted advisor to organizations embarking on internal and external transformation in life sciences and healthcare.
With over 20 years of biopharmaceutical strategy and operational leadership experience, Ms. Pomponio advises high growth life sciences companies on business development, product planning, and launch strategies in her role at Red Sky Partners. As Managing Director of Accendo Bio, she is accelerating innovation in patient services through social enterprise formation and nonprofit strategic planning. Previously, as VP of Corporate Affairs at Radius Health, she built public affairs and patient assistance capabilities and transformed company image for its first commercial launch. As Head of Science Affairs at AstraZeneca Pharmaceuticals, she led collaborations with patient associations and policy makers on alternative clinical trial design, drug repurposing, and biomarker qualification to streamline drug development. At Genzyme Corporation she expanded international markets through passage of orphan drug policy and drove novel pricing and reimbursement approaches, helping to grow the $5B global enzyme replacement business. She has public sector experience as Vice Consul and US Life Sciences Healthcare Advisor to the UK Government and as program analyst at the US Office of Management and Budget responsible for review of the US Human Genome Program.
Alice has a Master of Public Policy from Harvard University and a Bachelor of Science in Biology from MIT. She currently serves on Massachusetts Biotechnology Council Board of Directors and the American Cancer Society Eastern New England Board.